These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 31023357)

  • 21. Tigecycline in the treatment of multidrug-resistant Acinetobacter baumannii meningitis: Results of the Ege study.
    Sipahi OR; Mermer S; Demirdal T; Ulu AC; Fillatre P; Ozcem SB; Kaya Ş; Şener A; Bulut C; Tekin R; Kahraman H; Özgiray E; Yurtseven T; Sipahi H; Arda B; Pullukçu H; Taşbakan M; Yamazhan T; Aydemir S; Ulusoy S
    Clin Neurol Neurosurg; 2018 Sep; 172():31-38. PubMed ID: 29960893
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical evaluation of tigecycline in the treatment of nosocomial infection in a hospital in Taiwan.
    Wu MT; Chen HY; Ou TY; Kuo LN; Cheng KJ; Lee WS
    Int J Clin Pharmacol Ther; 2014 Dec; 52(12):1030-6. PubMed ID: 25345432
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Monotherapy versus combination therapy for sepsis due to multidrug-resistant Acinetobacter baumannii: analysis of a multicentre prospective cohort.
    López-Cortés LE; Cisneros JM; Fernández-Cuenca F; Bou G; Tomás M; Garnacho-Montero J; Pascual A; Martínez-Martínez L; Vila J; Pachón J; Rodríguez Baño J;
    J Antimicrob Chemother; 2014 Nov; 69(11):3119-26. PubMed ID: 24970742
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Case Report of Successful Treatment of Extensively Drug-Resistant Acinetobacter baumannii Ventriculitis with Intravenous plus Intraventricular Tigecycline.
    Liu Y; Pu Z; Zhao M
    Antimicrob Agents Chemother; 2018 Nov; 62(11):. PubMed ID: 30104281
    [No Abstract]   [Full Text] [Related]  

  • 25. Clinical study on the safety and efficacy of high-dose tigecycline in the elderly patients with multidrug-resistant bacterial infections: A retrospective analysis.
    Xia G; Jiang R
    Medicine (Baltimore); 2020 Mar; 99(10):e19466. PubMed ID: 32150105
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Successful treatment of extensively drug-resistant
    Guo W; Guo SC; Li M; Li LH; Qu Y
    Antimicrob Resist Infect Control; 2018; 7():22. PubMed ID: 29456841
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Triple combination therapy with high-dose ampicillin/sulbactam, high-dose tigecycline and colistin in the treatment of ventilator-associated pneumonia caused by pan-drug resistant Acinetobacter baumannii: a case series study.
    Assimakopoulos SF; Karamouzos V; Lefkaditi A; Sklavou C; Kolonitsiou F; Christofidou M; Fligou F; Gogos C; Marangos M
    Infez Med; 2019 Mar; 27(1):11-16. PubMed ID: 30882373
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tigecycline Therapy for Nosocomial Pneumonia due to Carbapenem-Resistant Gram-Negative Bacteria in Critically Ill Patients Who Received Inappropriate Initial Antibiotic Treatment: A Retrospective Case Study.
    Wu X; Zhu Y; Chen Q; Gong L; Lin J; Lv D; Feng J
    Biomed Res Int; 2016; 2016():8395268. PubMed ID: 28044137
    [No Abstract]   [Full Text] [Related]  

  • 29. [Efficacy of extended-infusion of carbapenem plus sulbactam for ventilator-associated pneumonia caused by extensive drug-resistant
    Wang X; Hu Y; Que CL; Zhang H; Huang JJ; Cao J; Jin Z; Wang GF; Zhang W
    Zhonghua Yi Xue Za Zhi; 2017 Oct; 97(38):2996-3000. PubMed ID: 29061006
    [No Abstract]   [Full Text] [Related]  

  • 30. High tigecycline resistance in multidrug-resistant Acinetobacter baumannii.
    Navon-Venezia S; Leavitt A; Carmeli Y
    J Antimicrob Chemother; 2007 Apr; 59(4):772-4. PubMed ID: 17353223
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The global prevalence of multidrug-resistance among Acinetobacter baumannii causing hospital-acquired and ventilator-associated pneumonia and its associated mortality: A systematic review and meta-analysis.
    Mohd Sazlly Lim S; Zainal Abidin A; Liew SM; Roberts JA; Sime FB
    J Infect; 2019 Dec; 79(6):593-600. PubMed ID: 31580871
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of the ratio of the estimated area under the concentration-time curve to minimum inhibitory concentration (estimated AUIC) as a predictor of the outcome for tigecycline treatment for pneumonia due to multidrug-resistant bacteria in an intensive care unit.
    Xu Y; Jin L; Liu N; Luo X; Dong D; Tang J; Wang Y; You Y; Liu Y; Chen M; Yu Z; Hao Y; Gu Q
    Int J Infect Dis; 2019 May; 82():79-85. PubMed ID: 30878630
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tigecycline treatment experience against multidrug-resistant Acinetobacter baumannii infections: a systematic review and meta-analysis.
    Ni W; Han Y; Zhao J; Wei C; Cui J; Wang R; Liu Y
    Int J Antimicrob Agents; 2016 Feb; 47(2):107-16. PubMed ID: 26742726
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Successful treatment of postoperative multidrug-resistant Acinetobacter baumannii meningitis by tigecycline.
    Kooli I; Brahim HB; Kilani M; Gannouni C; Aouam A; Toumi A; Loussaief C; Hattab MN; Chakroun M
    J Glob Antimicrob Resist; 2016 Jun; 5():62-3. PubMed ID: 27436468
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Phase 3, open-label, non-comparative study of tigecycline in the treatment of patients with selected serious infections due to resistant Gram-negative organisms including Enterobacter species, Acinetobacter baumannii and Klebsiella pneumoniae.
    Vasilev K; Reshedko G; Orasan R; Sanchez M; Teras J; Babinchak T; Dukart G; Cooper A; Dartois N; Gandjini H; Orrico R; Ellis-Grosse E;
    J Antimicrob Chemother; 2008 Sep; 62 Suppl 1():i29-40. PubMed ID: 18684704
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Healthcare-Associated Pneumonia and Hospital-Acquired Pneumonia: Bacterial Aetiology, Antibiotic Resistance and Treatment Outcomes: A Study From North India.
    Kumar S; Jan RA; Fomda BA; Rasool R; Koul P; Shah S; Khan UH; Qadri SM; Masoodi SR; Mantoo S; Muzamil M
    Lung; 2018 Aug; 196(4):469-479. PubMed ID: 29691645
    [TBL] [Abstract][Full Text] [Related]  

  • 37. EVALUATION OF IN VITRO TIGECYCLINE ACTIVITY AGAINST MULTIDRUG-RESISTANT ACINETOBACTER BAUMANNII CLINICAL ISOLATES FROM POLAND.
    Paluchowska P; Nowak P; Skalkowska M; Bjdak A
    Acta Pol Pharm; 2017 May; 74(3):793-800. PubMed ID: 29513948
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In Vitro Interactions of Antibiotic Combinations of Colistin, Tigecycline, and Doripenem Against Extensively Drug-Resistant and Multidrug-Resistant Acinetobacter baumannii.
    Park GC; Choi JA; Jang SJ; Jeong SH; Kim CM; Choi IS; Kang SH; Park G; Moon DS
    Ann Lab Med; 2016 Mar; 36(2):124-30. PubMed ID: 26709259
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [The efficacy of the tigecycline-colistin association in the treatment of multi-resistant Acinetobacter baumannii meningitis].
    Regaieg K; Bahloul M; Turki O; Mnif B; Bouaziz M
    Med Mal Infect; 2017 Mar; 47(2):175-177. PubMed ID: 28215823
    [No Abstract]   [Full Text] [Related]  

  • 40. Clinical experience of tigecycline treatment in infections caused by extensively drug-resistant Acinetobacter spp.
    Moon SY; Peck KR; Chang HH; Kim SW; Heo ST; Son JS; Ryu SY; Moon C; Jung SI; Shin SY; Lee JA; Joung MK; Chung DR; Kang CI; Song JH
    Microb Drug Resist; 2012 Dec; 18(6):562-6. PubMed ID: 22775562
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.